1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69F08AE8450AF3A42852579660049872E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-science-liaison-support-for-KOLs-throughout-product-lifecycle?opendocument
18
19opendocument
2034.226.234.20
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Science Liaison

Medical Science Liaison Services Excellence: Providing Support for KOLs Throughout Product Lifecycle

ID: 5176


Features:

12 Info Graphics

27 Data Graphics

150+ Metrics

6 Narratives


Pages/Slides: 47


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Medical Science Liaison Services Excellence: Providing Support for KOLs Throughout Product Lifecycle"

STUDY OVERVIEW

As competition for the time and attention of key opinion leaders (KOLs) intensifies, pharmaceutical companies are increasingly turning to medical science liaisons to build and strengthen key relationships. This benchmarking research study explores best practices in the management of MSLs and their work with KOLs pre- and post-approval, capturing information about the strategies, structures, activities, tools, and tactics currently being used for this purpose.

Specifically, Best Practices, LLC conducted this study to identify valuable insights into MSL services structure as well as the roles and responsibilities of these services in relation to KOLs. The study offers powerful insights that MSL leaders will be able to use in the organization and deployment of MSLs. Additionally, this report provides information on how the roles of MSLs are evolving in the changing pharmaceutical environment.

Data presented in two segments: Total Benchmark Class and U.S.

KEY TOPICS

  • Changes in MSL services to KOLs
  • KOL Profiling
  • KOL Relationship Channels and Relationship Management
  • MSL Services Over Product Lifecycle
  • Best Practices and Key Performing Factors for MSLs

SAMPLE KEY METRICS
  • Changes that impact the way MSLs interact with KOLs
  • Ranking of most effective new technologies for serving KOLs
  • Rating importance of key channels for building strong working relationships with KOLs
  • Criteria most relevant for profiling a KOL's influence and impact
  • Frequency for MSLs providing various KOL services prior to drug approval
  • Frequency for MSLs providing various KOL services after drug approval
  • Best practices that inform the work and success of highest-performing MSLs

SAMPLE KEY FINDING
  • KOL Relationships Crucial : Insights from interviews and research range broadly from starting early to develop KOL relationships, seeding MSL resources early, committing to the Therapeutic Area to win influential investigators, and employing segmentation to identify and manage top KOLs and investigators.
  • Involve KOLs in Science to Create Ownership: Involve KOLs from Phase II onward. Get them to work with the compounds and oftentimes they will help you write the protocols and they will have a better understanding of its purpose.

METHODOLOGY


Thirty-five research Pharmaceutical and Medical Device executives from 30 companies participated in this project. The benchmark class, of global pharmaceutical and medical device companies, has been segmented into two classes based on geographic coverage (Total Benchmark and U.S. focus).

Industries Profiled:
Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Advanced Biohealing; Allergan; Amylin; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Scientific; Cephalon; EndoPharma; Eisai; Gambro; G.E. Healthcare; Genetech; GlaxoSmithKline; Ironwood Pharma; Kadmon Pharma; Laboratorios Esteve; Lantheus Medical Imaging; Metronic; Merck Sharp and Dohme; Novartis; Novo Nordisk; Onyx Pharma; Pfizer; QLT; Quidel; Shire; Takeda; Theravance; UCB

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.